Insight Molecular Diagnostics
IMDX | NASDAQ
$1.86
-$0.28 (-13.08%)
At close: Nov 16, 2026, 4:00 PM ET
$1.53
-$0.33 (-17.74%)
After-hours:
Nov 16, 2026, 7:55 PM ET
Insight Molecular Diagnostics Company Profile
Company profile explainedCompany Profile
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Key Executives
| Name | Position |
|---|---|
| Joshua Riggs | President, Chief Executive Officer & Director |
| Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. |
| Andrea Susan James | Chief Financial Officer |
| Yuh-Min Chiang | Chief Technology Officer |
| Donnie Purto | SVP of Sales & Sales Operations |
| Ekkehard Schutz | Chief Science Officer |
| James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer |
| Paul R. Billings FACP | Consulting Chief Medical Officer |
| Peter Hong | Vice President, General Counsel & Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
| Steven Tahmooressi | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jul 24, 2026 | S-8 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jun 17, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
Insight Molecular Diagnostics
| Country | United States |
| IPO Date | Dec 30, 2015 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Joshua Riggs |
Contact Details
2 International Plaza Dr. Nashville,
Tennessee 37217 United States
Stock Details
| Ticker Symbol | IMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C206 |
| ISIN Number | US68235C2061 |
| SIC Code | 2835 |
Add to Watchlist
Select watchlists to add or remove IMDX